When there is inflammation in the brain nerve, the key protein will be produced in the brain.
Previous literature pointed out that many brain diseases, such as neurodegenerative diseases, stroke, traumatic brain injury and multiple sclerosis, are closely related to neuroinflammation. When these diseases occur, a large number of Galectin-3 will be produced in the brain, but the function and pathological mechanism of this protein in the brain are still unclear. Chen Yizhuang, a special researcher, pointed out that the research team used HD as an experimental model and found that there were a large number of Galectin-3 and damaged lysosomes in microglia of HD mice.
If we can inhibit this key protein, it will help to slow down neurodegenerative diseases.
Chen Yizhuang, a special researcher, further explained that in inflammatory microglia, Galectin-3 binds to the intima of damaged lysosomes, which interferes with the clearance of damaged lysosomes by cells and aggravates the neuroinflammatory reaction. In other words, if Galectin-3 can be inhibited by drugs or genetic methods, it can not only improve the ability of cells to clear lysosomes, but also reduce the inflammatory reaction of microglia, slow down the course of neurodegenerative diseases and improve the symptoms and life span of HD mice.
Inhibition of key proteins-a new drug strategy for treating brain diseases in the future
In the experiment, the life span of mice with symptoms was only 13 ~ 14 weeks, but it was successfully extended by 5 days after Galectin-3 inhibition. Four years after the implementation of the plan, the mechanism of Galectin-3 in neuroinflammatory reaction has also been confirmed. Chen Yizhuang, a special researcher, said that this discovery can not only be effectively applied to neurodegenerative diseases such as Alzheimer's disease, but also be expected to become a new drug strategy in the future.
This article is authorized to reprint from the health care network.
Topic: Academia Sinica, Stroke, Huntington's Chorea, Neurodegeneration, Alzheimer's Disease, Chen Yizhuang.